Shionogi regains rights to Symproic

9 July 2018

Japan’s Shionogi (TYO: 4507) says that it has restored exclusive US rights to its opioid-induced constipation (OIC) treatment Symproic (naldemedine) that the company previously granted to its US partner Purdue Pharma, under their strategic partnership deal on the therapy entered into in December 2016, reports Pharma Japan.

Following US Food and Drug Administration approval in March last year, Shionogi and Purdue launched the drug in October for treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The Japanese firm, as of wrting, has not released any details as to whey the action is being taken.

Symproic joined a market that AstraZeneca’s (LSE: AZN) Movantik (naloxegol) and Valeant Pharmaceuticals International’s (TSX: VRX) Relistor (methylnaltrexone bromide) had been battling out in the opioid-induced constipation arena since winning their FDA approvals back in September 2014.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK